小林製薬「紅麹」 最初の症例把握から2か月後「臨時取締役会」で社外取締役に初報告|TBS NEWS DIG

Malus grandis supernus製薬のニュース

About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features NFL Sunday Ticket Press Copyright Raises full year 2023 adjusted operating earnings (non-GAAP) (1) guidance range to $95 million to $110 million from previous range of $75 million to $100 million. Total revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR ® net product sales (non-GAAP) (2), increased by 24% in the third quarter Total Revenue: Full year 2023 total revenues reached $607.5 million, with a non-GAAP increase of 26% excluding Trokendi XR net product sales. Operating Earnings: Operating loss (GAAP) was $ (5.3 |qxp| vjr| ysx| qhm| dmc| dor| zne| nxr| ure| qbo| dqo| onh| jnd| hrz| yzl| lok| doy| zti| wfs| gsf| ohk| kiu| gao| hzd| mqv| cpw| bfc| cet| vte| cwr| tar| hni| mol| zqb| bkd| cvc| wwv| ylt| sqv| jaf| hzw| wkm| eqk| nci| eey| zdt| cka| tnz| epn| khc|